AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 APR 17 - (NewsRx.com & NewsRx.net) -- Cell Genesys, Inc., (CEGE) has leased a 35,000 square-foot facility in Memphis, Tennessee, which it plans to use to manufacture the company's patient-specific GVAX lung cancer vaccines for both phase III clinical trials and potential market launch.
Memphis, one of the major shipping hubs in the world, was chosen to facilitate the efficient transport and distribution of patient vaccines to treatment centers across the United States.
The facility sets the stage for Cell Genesys' product development strategy for GVAX lung cancer vaccines which includes establishing a centrally located GMP (good manufacturing practices) facility to receive and ...